sentinel lymph node

(redirected from Sentinel node procedure)

sentinel lymph node

the first lymph node to receive lymphatic drainage from a malignant tumor; the sentinel nodes are identified as the first to take on a radionuclide or dye injected into the tumor; increasingly used in operations for melanoma and breast cancer; if the sentinel nodes are free of metastasis, more distal nodes are usually also free.
See also: signal lymph node.

sen·ti·nel lymph node

(sen'ti-nĕl limf nōd)
The first lymph node to receive lymphatic drainage from a malignant tumor; the sentinel node is identified as the first to take up a radionuclide or dye injected into the tumor; increasingly used in operations for melanoma and breast cancer; if the sentinel node is free of metastasis, more distal nodes are also free.
See also: signal lymph node

Sentinel lymph node

The first lymph node to receive lymph fluid from a tumor. If the sentinel node is cancer-free, then it is likely that the cancerous cells have not metastasized.
Mentioned in: Vulvar Cancer
References in periodicals archive ?
The sentinel node procedure is an adequate tool to identify lymph node metastasis in breast cancer.
Clinical relevance of parasternal uptake in sentinel node procedure for breast cancer.
For this reason, a sentinel node procedure can be considered in patients who will be treated with mastectomy or excision in an anatomic location that could compromise the performance of a future sentinel node procedure, the panel noted in the 2003 revised guidelines.
Prevention of futile sentinel node procedures in breast cancer: ultrasonography of the axilla and line-needle aspiration cytology are obligatory.
Rajesh Sehgal, MD, a medical oncologist and hematologist with expertise in diagnosing and treating breast and colon cancer, has extensive experience in research using sentinel node procedures in colon cancer.
Melanoma patients undergoing earlier sentinel node procedures experience less damage to their lymph nodes, and more importantly, improved survival rates following diagnosis and treatment.
Researchers from UCSD presented encouraging preliminary clinical findings at the 48th Annual Meeting of the Society of Nuclear Medicine regarding a compound (99mTc(DTPA) Mannosyl-Dextran) being evaluated as a radiotracer to identify lymphatic tissue in sentinel node procedures.
The proprietary compound is being developed as a radiotracer to identify lymphatic tissue in sentinel node procedures.
The initial clinical performance of the compound appears to overcome some of the shortcomings of the radiotracer currently used in sentinel node procedures," said Dr.
The compound, 99mTc (DTPA) -- Mannosyl-Dextran, is being developed as a radiotracer to identify lymphatic tissue in sentinel node procedures.